Neurizon Therapeutics Limited (ASX: NUZ), formerly known as PharmAust, is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon strategy is to accelerate access to effective ALS treatments for patients, while exploring NUZ-001’s potential for broader neurodegenerative applications. Through international collaborations and rigorous clinical programs, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders.
Company Details
- Employees
- 11
- Address
- 385 Bourke Street, Suite 2,level 11,australia
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- pharmaust.com
- Keywords
- Pharmaceutical, Biotechnology, Drug manufacturing, Motor Neurone Disease, Neurodegenerative diseases, Amyotrophic lateral sclerosis.
- HQ
- Melbourne, Victoria
Neurizon Questions
Neurizon's website is pharmaust.com
Neurizon's LinkedIn profile is https://au.linkedin.com/company/neurizon
Neurizon has
11 employees.
View email and phone details for 11
employees at Neurizon.
Neurizon's industry is
Biotechnology Research
Neurizon's categories are Biotechnology Research
